Spherix Global Insights Expands into Financial Services, Empowering Asset Managers and Hedge Funds with Critical Pharmaceutical Market Insights
Comprehensive market insights across over 40 indications in dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology, providing financial firms with the tools to evaluate brand launches and project market evolution. EXTON, PA., September 25th, 2024 – Spherix Global Insights, a leading independent market intelligence and advisory firm, is expanding its specialized offerings to buy-side financial […]
US Rheumatologists Believe Biogen’s Litifilimab Is the Leading SLE Pipeline Asset Poised to Offer Improvement Over Benlysta and Saphnelo Based on Clinical Trial Data
Despite favorable views on litifilimab, AbbVie’s Rinvoqand BMS’ Sotyktu capture the most prescriber interest for approval, accordingto Spherix Global Insights. EXTON, PA., September 12, 2024 — The systemic lupus erythematosus (SLE) advanced treatment landscape is poised for evolution, with multiple new therapies in development to treat this debilitating and chronic disease. While Biogen’s litifilimab has […]
Discrepancies Discovered in the Treatment of People with Refractory Epilepsy by Epileptologists vs General Neurologists
Epileptologists and general neurologists have different approaches to treating people with refractory epilepsy, according to the Market Dynamix: Adult Refractory Epilepsy (US) study conducted by Spherix Global Insights (Exton, PA). Researchers found that general neurologists treat approximately 25% of people with epilepsy who have developed refractory epilepsy, constituting a significant proportion of the overall patient […]
EU Nephrologists Foresee Travere/CSL Vifor’s FILSPARITM (sparsentan) Transforming IgA Nephropathy Treatment as the First Non-Immunosuppressive Therapy
Data from Spherix Global Insights’ second annual EU IgAN patient chart audit indicates that even with the EMA approval of FILSPARITM (sparsentan), opportunities for pipeline agents to make an impact remain. EXTON, PA., April 30, 2024 – Over the past several years, glomerular diseases have garnered significant attention from the nephrology industry, largely driven by […]
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for the Treatment of Ulcerative Colitis, but Future Projections Reveal a Highly Evolving Market
Takeda’s line extension has outpaced other concurrent launches in adoption and familiarity three months post launch, according to Spherix Global Insights. Exton, PA., March 22, 2024 – The end of 2023 introduced several new treatment options for patients suffering from ulcerative colitis (UC). Among them is Eli Lilly’s Omvoh (mirikizumab), the first FDA approved IL-23 […]
Stakes Are High for Regeneron’s Eylea HD as Genentech’s Vabysmo Continues to Gain Momentum, Prompting Doctors to Weigh Their Options Between Two Industry Titans, According to Spherix Global Insights
Navigating the landscape of Wet AMD Therapies During AMD Awareness Month EXTON, PA., February 8, 2024 — As Age-Related Macular Degeneration (AMD) Awareness Month unfolds, illuminating the visual challenges faced by millions of Americans with AMD, the need for optimal treatment solutions becomes increasingly evident. Wet AMD poses a particularly severe threat to vision, necessitating […]
Market Study Reports Secukinumab Emerged as a Leading Treatment for HS
To gauge the impact and evolving landscape of HS treatment post-secukinumab approval, Spherix Global Insights conducted research with more than 100 US dermatologists. In a significant development for patients with hidradenitis suppurativa (HS), the FDA granted approval to secukinumab (Cosentyx, Novartis) last fall. This marked a milestone as secukinumab became the second biologic, alongside adalimumab […]
Chart review shows nephrologists prescribing more SGLT2 inhibitors
A chart review completed by Spherix Global Insights shows that more nephrologists are using SGLT2 inhibitors to treat patients with chronic kidney disease, according to a press release. “Analysis of 1,052 chronic kidney disease non-dialysis patient charts reveals continuous growth in SGLT2 inhibitor use and expanding opportunities for [mineralocorticoid receptor agonists] MRAs and [glucagon-like peptide-1] […]
Novartis’ Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for Significant Future Adoption at the Expense of AbbVie’s Humira
Despite the expanded armamentarium, Cosentyx has not impacted dermatologists’ perceived unmet need for new HS treatment options, according to Spherix Global Insights. [Exton, PA., January 10, 2024] — In late October 2023, the FDA granted approval to Novartis’ Cosentyx (secukinumab) for treating hidradenitis suppurativa (HS), marking it as the second biologic approved alongside AbbVie’s Humira […]
US biosimilar market in 2023: Sea change or slow drip?
News pertaining to biosimilars came at a fast and furious pace in 2023. This was the year of the big “deluge” in biosimilars, including those designated as interchangeable, hitting the rheumatology market in the United States. As many as nine biosimilars for adalimumab (Humira, AbbVie) alone became available for the first time for U.S. patients, […]
